FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186606703> ?p ?o ?g. }

• W3186606703 abstract "The purpose of this study was to retrospectively analyze the safety and clinical efficacy of anlotinib combined with dose-dense temozolomide (TMZ) as the first-line therapy in the treatment of recurrent glioblastoma (rGBM).We collected the clinical data of 20 patients with rGBM. All patients received anlotinib (12 mg daily, orally for 2 weeks, discontinued for 1 week, repeated every 3 weeks) combined with dose-dense TMZ (100 mg/m2, 7 days on with 7 days off) until the disease progressed (PD) or adverse effects (AEs) above grade 4 appeared. Grade 3 AEs need to be restored to grade 2 before continuing treatment, and the daily dose of anlotinib is reduced to 10 mg. The patients were reexamined by head magnetic resonance imaging (MRI) every 1 to 3 months. The therapeutic effect was evaluated according to Response Assessment in Neuro-Oncology (RANO) criteria. The survival rate was analyzed by Kaplan-Meier survival curve analysis. The baseline of all survival index statistics was the start of anlotinib combined with dose-dense of TMZ. National Cancer Institute-Common Terminology Criteria Adverse Events version 4.0 (NCI-CTCAE 4.0) was used to evaluate AEs.Twenty cases of rGBM were evaluated according to the RANO criteria after treatment with anlotinib and dose-dense TMZ, including five cases of stable disease (SD), thirteen cases of partial response (PR), one case of complete response (CR), and one case of PD. The median follow-up time was 13.4 (95% CI, 10.5-16.3) months. The 1-year overall survival (OS) rate was 47.7%. The 6-month progression-free survival (PFS) rate was 55%. In the IDH wild type group, the median PFS and median OS were 6.1 and 11.9 months, respectively. We observed that AEs associated with treatment were tolerable. One patient stopped taking the drug because of cerebral infarction. There were no treatment-related deaths.Anlotinib combined with dose-dense TMZ for the first-line therapy showed good efficacy in OS, PFS, ORR, and DCR in the treatment of rGBM, and the AEs were tolerant. Randomized controlled clinical trials investigating the treatment of rGBM with anlotinib are necessary." @default.
• W3186606703 created "2021-08-02" @default.
• W3186606703 creator A5002455944 @default.
• W3186606703 creator A5028296024 @default.
• W3186606703 creator A5055212310 @default.
• W3186606703 creator A5080556184 @default.
• W3186606703 date "2021-07-20" @default.
• W3186606703 modified "2023-10-03" @default.
• W3186606703 title "Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma" @default.
• W3186606703 cites W1546884011 @default.
• W3186606703 cites W1751749102 @default.
• W3186606703 cites W1862835589 @default.
• W3186606703 cites W1998006373 @default.
• W3186606703 cites W2013816626 @default.
• W3186606703 cites W2044538065 @default.
• W3186606703 cites W2047631667 @default.
• W3186606703 cites W2055764003 @default.
• W3186606703 cites W2060427266 @default.
• W3186606703 cites W2096287682 @default.
• W3186606703 cites W2096415778 @default.
• W3186606703 cites W2097459031 @default.
• W3186606703 cites W2101922439 @default.
• W3186606703 cites W2105932257 @default.
• W3186606703 cites W2528424364 @default.
• W3186606703 cites W2604398481 @default.
• W3186606703 cites W2663694575 @default.
• W3186606703 cites W2768388636 @default.
• W3186606703 cites W2773039266 @default.
• W3186606703 cites W2791378348 @default.
• W3186606703 cites W2791602004 @default.
• W3186606703 cites W2791667474 @default.
• W3186606703 cites W2793605704 @default.
• W3186606703 cites W2795758525 @default.
• W3186606703 cites W2808043936 @default.
• W3186606703 cites W2883308541 @default.
• W3186606703 cites W2888534569 @default.
• W3186606703 cites W2889570909 @default.
• W3186606703 cites W2903289999 @default.
• W3186606703 cites W2946965310 @default.
• W3186606703 cites W2947000777 @default.
• W3186606703 cites W2981930459 @default.
• W3186606703 cites W2990419607 @default.
• W3186606703 cites W2990424668 @default.
• W3186606703 cites W2999607433 @default.
• W3186606703 cites W3007595469 @default.
• W3186606703 cites W3008699358 @default.
• W3186606703 cites W3012539638 @default.
• W3186606703 cites W3087018809 @default.
• W3186606703 cites W3105911727 @default.
• W3186606703 doi "https://doi.org/10.3389/fonc.2021.687564" @default.
• W3186606703 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8330423" @default.
• W3186606703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34354945" @default.
• W3186606703 hasPublicationYear "2021" @default.
• W3186606703 type Work @default.
• W3186606703 sameAs 3186606703 @default.
• W3186606703 citedByCount "5" @default.
• W3186606703 countsByYear W31866067032022 @default.
• W3186606703 countsByYear W31866067032023 @default.
• W3186606703 crossrefType "journal-article" @default.
• W3186606703 hasAuthorship W3186606703A5002455944 @default.
• W3186606703 hasAuthorship W3186606703A5028296024 @default.
• W3186606703 hasAuthorship W3186606703A5055212310 @default.
• W3186606703 hasAuthorship W3186606703A5080556184 @default.
• W3186606703 hasBestOaLocation W31866067031 @default.
• W3186606703 hasConcept C121332964 @default.
• W3186606703 hasConcept C126322002 @default.
• W3186606703 hasConcept C126838900 @default.
• W3186606703 hasConcept C141071460 @default.
• W3186606703 hasConcept C142424586 @default.
• W3186606703 hasConcept C143409427 @default.
• W3186606703 hasConcept C143998085 @default.
• W3186606703 hasConcept C197934379 @default.
• W3186606703 hasConcept C2776194525 @default.
• W3186606703 hasConcept C2776694085 @default.
• W3186606703 hasConcept C2777389519 @default.
• W3186606703 hasConcept C2777793932 @default.
• W3186606703 hasConcept C2780964509 @default.
• W3186606703 hasConcept C2989005 @default.
• W3186606703 hasConcept C502942594 @default.
• W3186606703 hasConcept C509974204 @default.
• W3186606703 hasConcept C71924100 @default.
• W3186606703 hasConcept C87355193 @default.
• W3186606703 hasConceptScore W3186606703C121332964 @default.
• W3186606703 hasConceptScore W3186606703C126322002 @default.
• W3186606703 hasConceptScore W3186606703C126838900 @default.
• W3186606703 hasConceptScore W3186606703C141071460 @default.
• W3186606703 hasConceptScore W3186606703C142424586 @default.
• W3186606703 hasConceptScore W3186606703C143409427 @default.
• W3186606703 hasConceptScore W3186606703C143998085 @default.
• W3186606703 hasConceptScore W3186606703C197934379 @default.
• W3186606703 hasConceptScore W3186606703C2776194525 @default.
• W3186606703 hasConceptScore W3186606703C2776694085 @default.
• W3186606703 hasConceptScore W3186606703C2777389519 @default.
• W3186606703 hasConceptScore W3186606703C2777793932 @default.
• W3186606703 hasConceptScore W3186606703C2780964509 @default.
• W3186606703 hasConceptScore W3186606703C2989005 @default.
• W3186606703 hasConceptScore W3186606703C502942594 @default.
• W3186606703 hasConceptScore W3186606703C509974204 @default.
• W3186606703 hasConceptScore W3186606703C71924100 @default.
• W3186606703 hasConceptScore W3186606703C87355193 @default.

• next